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AbstrACt
background Characterizing expression profiles of 
different immune checkpoint molecules are promising 
for personalized checkpoint inhibitory immunotherapy. 
Gliomas have been shown as potential targets for immune 
checkpoint inhibitors recently. Our study was performed 
to determine coexpression levels of two major B7 immune 
regulatory molecules programmed death ligand 1 (PD- L1) 
and B7- H4, both of which have been demonstrated to 
inhibit antitumor host immunity in gliomas.
Methods We assessed tumor tissues from stage II–IV 
primary gliomas (n=505) by immunohistochemistry 
(IHC) for protein levels of both PD- L1 and B7- H4. Gene 
coexpression analysis assessing clusters based on 
extent of PD- L1/B7- H4 classifier genes expression were 
investigated in two transcriptome datasets (The Cancer 
Genome Atlas and Chinese Glioma Genome Atlas). In 
addition, levels of immune cell infiltrates were estimated 
with IHC and RNA- seq data for assessing the tumor 
immune microenvironment of PD- L1/B7- H4 subgroups.
results High expression of PD- L1 and B7- H4 in gliomas 
was 23% and 20%, respectively, whereas coexpression of 
two proteins at high levels was limited to 2% of the cases. 
Comparable results were seen in RNA- seq datasets where 
PD- L1 mRNA expression levels negatively correlated with 
that of B7- H4. Gene coexpression modules clustered 
within each grade of gliomas demonstrated lack of double- 
high modules (cluster with high expression of both PD- L1 
and B7- H4 classifier genes). B7- H4 mRNA expression 
levels showed negative correlation with extent of immune 
cell infiltration and High- B7- H4 module gliomas (high B7- 
H4 but low PD- L1 classifier genes expression) had less 
tumor- infiltrating lymphocytes (TILs) and tumor- associated 
macrophages (TAMs). IHC assessment also showed few 
TILs and TAMs in High- B7- H4 subgroup gliomas.
Conclusions The majority of gliomas express PD- L1 or 
B7- H4, however, coexpression of both at high levels is 
minimal. The high- B7- H4 patients could be considered as 
‘super- cold’ gliomas with significantly deficient in TILs, 
suggesting that B7- H4 might inhibit T- cell trafficking into 
the central nervous system. This study demonstrated that 
PD- L1 and B7- H4 may serve as mutually compensatory 
immune checkpoint molecules in gliomas for immune 
targeted or active- specific immunotherapy. The distinct 
B7- H4 pathways modulating T- cell function and immune 
evasion in glioma patients deserved to be further explored 
in the future during immunotherapy.
bACkground
Tumor immunotherapy has shown significant 
breakthroughs in recent years, particularly 
with the approval of immune checkpoints 
inhibitors (ICIs) and T- cell therapy.1 Studies 
with ICIs have demonstrated durable clinical 
responses and prolonged survival in various 
solid tumors such as melanoma, targeting 
programmed death 1 (PD-1) and programmed 
death ligand 1 (PD- L1) molecules.2 Since the 
dogma that the central nervous system (CNS) 
is an immune- privileged site for tumors 
has been challenged with recent immune 
profiling studies, immunotherapy has been 
used more frequently to treat gliomas, the 
most common and lethal tumor in the CNS.3 
Although the immunotherapy has increasing 
appeal for the treatment of cancer, only a 
fraction of specific cancer type patients has 
overall long- term survival benefits.2 4 Clini-
cally, useful immune- related biomarkers are 
needed to define which patients will benefit 
and to triage patients into optimal immuno-
therapy protocols.
The PD- L1 expression in tumor microen-
vironment (TME) has been considered as a 
predictive biomarker for anti- PD-1/PD- L1 
therapies. High PD- L1 expression in patients 
was correlated with high response rate for 
PD-1/PD- L1 blockade.5 6 Nevertheless, thera-
peutic resistance in patients with high PD- L1 
expression and immunotherapy- insensitivity 
in those with low PD- L1 expression neces-
sitate characterization of additional immu-
nosuppressive biomarkers and a deeper 
understanding of immune escape mecha-
nisms.7 Previous studies demonstrated that 
the majority of gliomas were PD- L1 positive 
but only a small number of patients had high 
expression.8 9 Despite various clinical trials 
with PD-1/PD- L1 inhibitors in gliomas, the 
utility and reliability of PD- L1 as an immuno-
suppressive biomarker remains insufficient.3
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B7- H4 (B7x /B7S1) is one of the T- cell costimulatory 
and coinhibitory B7 family molecules overexpressed in 
various malignant tumors, including gliomas.10 We have 
recently reported that B7- H4 expression is associated 
with glioma grade and clinical outcome.11 In addition, 
blockade of B7- H4 has been shown to enhance T- cell 
activation.12 In our previous study, we demonstrated 
that B7- H4 activation in glioma associated macrophage/
microglia establishes a cross- talk with glioma stem cells, 
which leads to immunosuppression.11 Considering 
mutual exclusive expression of PD- L1 and B7- H4 in lung 
cancer13–15 and breast cancer,16 and that glioblastoma 
multiforme (GBM) patients with low expression of B7- H4 
benefited from dendritic cell (DC) vaccine,4 we specu-
lated that B7- H4 may be another promising biomarker 
for immunotherapy in glioma patients as a supplement 
for PD- L1. Nevertheless, the relationship between PD- L1 
and B7- H4 in gliomas remains unexplored.
In this study, using immunohistochemistry (IHC), we 
evaluated protein levels of PD- L1 and B7- H4 in a large 
glioma patient cohort in order to determine their coex-
pression status. Two transcriptomics datasets with mRNA 
expression were also used to investigate the relationship 
between PD- L1 and B7- H4 by correlation and gene coex-
pression module analyzes. To a significant extent, we 
found limited coexpression of PD- L1 and B7- H4, which 
indicates that the PD- L1 alone is not sufficient to define 
immune evasion strategy in gliomas and that B7- H4 is 
also a significant component of the immune escape 
mechanism.
Methods
specimens and tissue microarrays
Archival FFPE (formalin fixed paraffin embedded) tumor 
tissue sections were obtained from patients diagnosed 
with primary gliomas(n=505) when undergone tumor 
resection between 2001 and 2017 at the Department 
of Neurosurgery, Huashan Hospital, Fudan University. 
Three FFPE tissue microarrays (TMA) sections including 
276 samples were prepared using 1.5 mm tissue cores, and 
the other 229 specimens were overlapped as described 
previously.4 The tumor area for each core in TMA was 
confirmed by the neuropathologist using HE staining. 
Detailed clinicopathological characteristics are available 
in online supplementary table S1 (online supplementary 
additional file 2: table S1).
Immunohistochemistry
FFPE glioma tumor tissue sections were deparaffinized in 
xylene and rehydrated through a graded series of ethanol 
concentrations; the sections were blocked with 3% H2O2 
for 20 min at room temperature. Sections for B7- H4 and 
CD3 were retrieved by Tris- Ethylene Diamine Tetraacetie 
Acid (EDTA, pH=9.0) and sodium citrate buffer (pH=6.0) 
respectively, and sections for PD- L1 and CD163 were 
retrieved by lycium hydrochloric acid (pH=6.0). B7- H4 
antibody (Ab), PD- L1 Ab and CD3 Ab were diluted at 
the same dilution of 1:100, while CD163 Ab was diluted 
at 1:50. After incubated overnight at 4℃, primary Abs 
were washed out and followed by VECTASTAIN ABC 
kit (PK-6200) for 30 min. DAB substrate kit (SK4100) 
was used to develop DAB chromogen and Hematoxylin 
staining solution was used to stain nuclei. The PD- L1, 
CD3 and CD163 Abs have been validated in gliomas by 
previous studies (online supplementary additional file 
2: table S2). For B7- H4 Ab, GL261 cells transfected with 
human B7- H4 gene were prepared as FFPE cell blocks 
(online supplementary additional file 4: supplementary 
materials and methods, additional file 1: figure S1); IHC 
was performed with or without primary Ab as positive and 
negative controls, respectively. FFPE cell blocks derived 
from GL261 cells transfected with an empty vector were 
used for negative controls. B7- H4- positive GL261 cells 
showed brownish stain while cells in negative controls 
were stained with hematoxylin showing blue nuclei 
(online supplementary additional file 1: figure S1). More-
over, the staining in normal control brain tissues (non- 
tumor tissues) with primary Abs (online supplementary 
additional file 1: figure S1) and in the tumor tissue 
sections without primary Abs were conducted as negative 
controls for each targeted protein.
Manual quantification of IhC
B7- H4 and PD- L1 specific IHC staining was semiquanti-
tatively scored based on the intensity and percentage as 
previously described.4 11 Briefly, the cells with partial or 
complete IHC staining at any intensity are considered 
as positive cells. The positive reaction of B7- H4/PD- L1 
was scored into four grades according to the intensity of 
the staining: 0, 1, 2 and 3. The percentages of B7- H4/
PD- L1–positive cells were also scored into four catego-
ries: 0 (0%), 1 (1%–33%), 2 (34%–66%) and 3 (67%–
100%). The sum of the intensity and percentage scores 
was used as the final IHC score from 0 to 6. The staining 
pattern of the tissues was defined as follows according 
to the final IHC score: low expression, 0–2; high expres-
sion, 3–6. Extent of TIL presence in TMA slide cores was 
assessed by semiquantitative measurement of the density 
of CD3 positive (CD3+) cells, and was scored as previously 
published9 17: 1, no (less than four TILs in the entire spec-
imen) or sporadic (more than four but no accumulation) 
CD3+ cells; 2, moderate numbers of CD3+ cells (single 
areas with accumulation of TILs); 3, abundant occur-
rence of CD3+ cells (TILs throughout the tumor section); 
and 4, highly abundant occurrence of CD3+ cells (high 
frequency of TILs throughout the entire tumor section). 
The IHC of CD163 was assessed as the percentage of posi-
tive cells related to the total cell number.
The IHC staining was analyzed by two observers blinded 
to clinical characteristics. A consensus for the final scores 
of PD- L1, B7- H4 and CD3 were reached for each sample, 
and the mean number of positive proportions from 
two observers was calculated for CD163. Representa-
tive photographs of each category for staining intensity 
and percentage of PD- L1/B7- H4 were shown in online 
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supplementary figure S2 (online supplementary addi-
tional file 1: figure S2). Fleiss’s kappa for the categorical 
values (high expression and low expression for PD- L1/
B7- H4) and ranked numerical values (1, 2, 3 and 4 for 
CD3+) were calculated for the interobserver agreement 
between two observers. The correlation analysis based 
on Spearman’s testing for continuous numerical values 
(positive proportion for CD163+) was performed to elim-
inate a potential interobserver variation of manual quan-
tification. Concordant agreements were observed for 
the interobserver assessment in each protein molecule 
assessed (online supplementary additional file 2: table S3 
and S4).
transcriptome data analysis
Two published glioma transcriptome datasets were 
downloaded from The Cancer Genome Atlas (TCGA) 
and Chinese Glioma Genome Atlas (CGGA).18 19 RNA 
sequencing (RNA- seq) expression data were further 
normalized using upper quartile FPKM (FPKM- UQ) 
as described in TCGA website. The RNA- seq data were 
log2 transformed before analysis between several groups. 
Patient demographics were obtained from each data 
portal. Differentially expressed genes (DEGs) between 
different groups were identified using DESeq2 package20 
with the criteria of |fold change|>2 and the false discovery 
rate <0.05).
Prediction of Pd-L1/b7-h4 classifier genes and clustering 
analysis
In order to identify PD- L1/B7- H4 classifier genes (genes 
that are coexpressed with PD- L1 or B7- H4) in the training 
dataset (TCGA), we used biweight midcorrelation (bicor) 
to evaluate ‘similarity’ between gene expression profiles, 
which is thought to be a good measurement for gene 
coexpression module analysis.21 First, bicor for each pair 
of genes was calculated, and the 95th percentile of the 
bicor values was defined as the cut- off, which was 0.37027. 
Genes whose patterns are highly correlated to PD- L1 or 
B7- H4 were further selected if positively correlated with 
each other (the bicor values are larger than the cut- off). 
Finally, 62 PD- L1 classifier genes and 35 B7- H4 classifier 
genes were determined (online supplementary additional 
file 2: table S5).
We performed non- negative matrix factorization 
(NMF) algorithm with the R package NMF22 to define 
glioma clusters.23 The following steps were used to deter-
mine the optimal factorization rank (the number of 
clusters) in each data set: (1) Random expression data 
were generated by permutating columns (patients) in the 
original dataset; (2) We performed 100 runs of NMF and 
select the best fitted model for both the original and the 
corresponding random data sets with rank from 2 to 7, 
and obtained the residual sum of squares (RSS) for each 
rank; (3) The smallest rank was selected if RSS decrease 
is less than that in random data as described previ-
ously.24 With the optimal rank k, the partitioning around 
medoids algorithm was used to perform clustering on the 
coefficient matrix of each run of the corresponding NMF 
model where the number of clusters is k. The consensus 
matrix of clustering was then generated and the final 
clusters of samples were determined by cutting the hier-
archical clustering of the consensus matrix into k groups.
bioinformatic analysis
The R package ESTIMATE (Estimation of STromal and 
Immune cells in MAlignant Tumour tissues using Expres-
sion data) was applied to predict tumor purity based on 
the estimation of stromal and immune scores in tumor 
tissues using gene expression data.25 Samples from TCGA 
having genomic sequencing data were labeled with 
ABSOLUTE purity instead of ESTIMATE purity and were 
extracted from previous paper.26 The gene set variation 
analysis (GSVA) package of R was used to calculate infil-
trating scores for 22 immune cell subtypes and microglia.27 
In order to rule out possible bias from different algo-
rithms, we calculated absolute immune cell fractions for 
22 immune cell populations with CIBERSORT (Cell- type 
Identification By Estimating Relative Subsets Of RNA 
Transcripts),28 followed by being corrected using tumor 
purity per sample.29 Gene ontology (GO) term enrich-
ment analysis was carried out with R language using clus-
terProfiler packages.30 Two gene sets extracted from the 
Molecular Signatures Database (immune system process, 
M13664; immune response M19817) were used to profile 
immune phenotype between modules using principal 
components analysis (PCA).31 Ontology gene sets were 
obtained from MSigDB32 and the results of gene set 
enrichment analysis (GSEA) were visualized by cluster 
Profiler package.30
statistical analyses
Spearman’s rank correlation coefficient was used for 
correlation analysis. χ2 test or Fisher’s exact test was 
used for categorical variables and differences in contin-
uous variables between groups were evaluated by t- test 
or one- way analysis of variance. All tests were two- sided 
performed by SPSS software or R language and p<0.05 
was considered statistically significant labeled with * 
for p<0.05, ** for p<0.01, *** for p<0.001, and **** for 
p<0.0001.
resuLts
Assessment of Pd-L1 and b7-h4 expression in gliomas
Although the majority of newly diagnosed gliomas 
patients were PD- L1- positive (61%, IHC score >0) in the 
IHC cohort (n=505), only 23.4% of them were defined 
as high expression of PD- L1 (IHC score >2). For GBM 
patients in this cohort, about 73.5% samples were PD- L1- 
positive while 29.1% were determined as high expression. 
For lower grade gliomas (LGG, grades II and III), we 
found that 49.4% of patients expressed PD- L1 while 18.5% 
expressed it at high levels. The relationship between 
PD- L1 expression and clinicopathological variables were 
investigated as shown in online supplementary table S6 
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Figure 1 Coexpression with high level of both PD- L1 and B7- H4 expression was limited in the IHC cohort. Distributions of 
PD- L1/B7- H4 subgroups in gliomas (A). Representative cases of PD- L1/B7- H4 subgroups were shown with the same area for 
per sample: case 1, High- PD- L1 subgroup; case 2, high- B7- H4 subgroup; case 3, double- Low subgroup; case 4, double- High 
subgroup (B). Magnification, ×40 objective; Bar, 20 um. PD- L1, programmed death ligand 1.
(online supplementary additional file 2: table S6). Tumor 
location, histology, WHO grade and IDH gene status 
had a significant correlation with PD- L1 expression. The 
percentages of B7- H4- positive and B7- H4 high- expression 
samples were 54.1% and 19.6% in the IHC cohort, 53.8% 
and 14.1% in GBM patients, and 54.2% and 24.4% in 
LGG patients, respectively. The B7- H4 expression was 
significantly associated with gender, histology, WHO 
grade, TERT gene status and chromosome 1 p/19q 
(Chr1p/19q) status (online supplementary additional 
file 2: table S6).
Pd-L1 and b7-h4 coexpression is limited in gliomas
In the cohort assessed for IHC (n=505), 61% of glioma 
patients had low expression of both PD- L1 and B7- H4 
(double- low subgroup), 20% had high expression 
of PD- L1 but low expression of B7- H4 (high- PD- L1 
subgroup) and 17% had high expression of B7- H4 but 
low expression of PD- L1 (high- B7- H4 subgroup). Interest-
ingly, only 2% of the patients had high expression of both 
PD- L1 and B7- H4 (double- high subgroup, figure 1A). 
Significant associations were detected in histology, WHO 
grade, IDH status, TERT gene status and Chr1p/19q 
status among PD- L1/B7 H4 subgroups (online supple-
mentary additional file 1: figure S3 and additional file 
2: table S7). Representatives of these subgroups with 
mutually exclusive expression of PD- L1 and B7- H4 are 
shown in figure 1B. Moreover, H- scores of PD- L1 and 
B7- H4 in TMA cores (online supplementary additional 
file 4: online supplementary materials and methods) also 
showed limited coexpression of both biomarkers (online 
supplementary additional file 1: figure S4).
In order to avoid possible bias by tumor tissue sampling 
in the TMA cores, we analyzed the mRNA expression 
levels of PD- L1and B7- H4 based on two published RNA- 
seq datasets obtained from TCGA and CGGA. As shown 
in figure 2, a similarly restricted coexpression pattern 
was observed in TCGA cohort (figure 2A, n=666) and 
CGGA cohort (figure 2B, n=305) with significant nega-
tive correlation between PD- L1 and B7- H4. Moreover, we 
found most other checkpoint immune molecules that 
have been verified as therapeutic targets in clinical or 
preclinical trials were tightly associated with PD- L1 while 
demonstrating mutually exclusive expression with B7- H4 
(figure 2).
Identification of Pd-L1/b7-h4 classifier genes
Identification of gene coexpression modules around 
key signaling pathways may enable molecular classifi-
cation of gliomas. We, therefore, decided to generate 
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Figure 2 Correlation analysis between estimable checkpoint molecules in two transcriptome datasets showed mutual 
exclusive expression profiles between PD- L1 and B7- H4. TCGA dataset (A). CGGA dataset (B). CGGA, Chinese Glioma 
Genome Atlas; PD- L1, programmed death ligand 1; TCGA, The Cancer Genome Atlas.
gene coexpression modules by classifier genes that are 
strongly associated with PD- L1 and B7- H4 using tran-
scriptomics datasets. The classifier genes were extracted 
from TCGA training set (n=666), identifying genes with 
similar expression patterns with PD- L1 (62 genes) and 
B7- H4 (35 genes), analyzes of which could help decipher 
key signaling pathways related to these molecules (online 
supplementary additional file 2: table S5). GO analysis 
for classifier genes revealed that they were significantly 
enriched in many biological processes related to immune 
responses and intercellular communication (online 
supplementary additional file 2: table S8).
Pd-L1/b7-h4 classifier genes identified glioma subtypes
According to the expression profiles of predicted PD- L1/
B7- H4 classifier genes, each grade of gliomas from 
TCGA could be classified into three new subtypes: high- 
PD- L1 (high expression of PD- L1 but low expression of 
B7- H4 classifier genes), high- B7- H4 (high expression of 
B7- H4 but low expression of PD- L1 classifier genes) and 
double- low modules (low expression of both PD- L1 and 
B7- H4 classifier genes) (figure 3A and online supple-
mentary additional file 1: figures S5a and S6a). Here, 
we confirmed that high- PD- L1 module gliomas highly 
expressed PD- L1 with lower levels of B7- H4 while High- 
B7- H4 module gliomas highly expressed B7- H4 with 
lower levels of PD- L1 (online supplementary additional 
file 1: figures S5b, S6b and S7a). Strikingly, we found 
there was no double- High module (high PD- L1 and high 
B7- H4 classifier genes expression) which supported our 
previous finding of a restricted coexpression pattern 
between PD- L1 and B7- H4. We then used the transcrip-
tome dataset from CGGA to validate such classification 
criteria (figure 3B and online supplementary additional 
file 1: figures S7- S9). The number of possible glioma 
subtypes was determined based on appropriate rank 
number with stable cophenetic correlation coefficients, 
which is consistent with the above observations (online 
supplementary additional file 1: figures S10- S12). In addi-
tion, most of the clinicopathological parameters exhib-
ited statistically significant differences between different 
subtypes for each grade, such as age, histology, TCGA 
subtype and molecular classifications (online supplemen-
tary additional file 2: tables S9- S14). Further investiga-
tion of the relationship between new subtypes and known 
TCGA subtypes revealed that almost all of the mesen-
chymal subtype belonged to the high- PD- L1 subtype, 
whereas the high- B7- H4 subtype mainly were contained 
in the proneural subtype.
Immune microenvironment is differentially activated in Pd-L1/
b7-h4 modules
Considering that many PD- L1/B7- H4 classifier genes 
are related to tumor–immune system interactions, it is 
possible that modules defined by PD- L1/B7- H4 signa-
tures may be distinct in terms of the tumor immune 
microenvironment. Indeed, the immune and stromal 
score calculated by ESTIMATE in TCGA set revealed that 
gliomas in the High- PD- L1 module had more immune 
cell infiltrations whereas a significantly smaller immune 
infiltrating score was obtained for High- B7- H4 module 
(figure 4A and online supplementary additional file 1: 
figures S13a and S14a). We also found that high- B7- H4 
module had higher tumor purity has been shown to 
contribute to poor immune cell infiltration (figure 4B 
and online supplementary additional file 1: figures S13b 
and S14b). The GSVA score represented the extent of 23 
immune cells infiltrations suggested smaller fractions of 
TILs and tumor- associated macrophages (TAMs) in the 
high- B7- H4 module (figure 4C and online supplemen-
tary additional file 1: figures S13c and S14c). Further 
evaluation of absolute fractions of different immune 
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Figure 3 Gene coexpression modules in each glioma grade using PD- L1/B7- H4 classifier genes showed mutual exclusive 
expression profiles in RNA- seq datasets without double- High modules. The appropriate numbers of clusters were determined 
as mentioned in Methods (additional file 1: online supplementary additional file 1: figures S10- S12). The grade 4 gliomas in 
TCGA dataset were clustered into three modules (A). The grade 4 gliomas in CGGA dataset were clustered into four modules 
(additional file 1: online supplementary additional file 1: figure S33) and could be combined into three modules (B). CGGA, 
Chinese Glioma Genome Atlas; PD- L1, programmed death ligand 1; TCGA, The Cancer Genome Atlas.
cell types verified that high- PD- L1 module tumors had 
more TILs and TAMs than tumors of the high- B7- H4 
module (online supplementary additional file 1: figures 
S15a, S16a and S17a). The data from CGGA validation 
dataset also showed that high- B7- H4 module gliomas 
were deficient of TILs in the TME (online supplemen-
tary additional file 1: figures S15b, S16b, S17b and S18- 
S20). Correlation analysis revealed that B7- H4 expression 
level negatively correlates with TILs and TAMs presence 
(online supplementary additional file 1: figures S21- S25). 
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Figure 4 Assessment of tumor immune microenvironment among PD- L1/B7- H4 modules in grade 4 gliomas from TCGA 
dataset. ESTIMATE evaluation showed less immune infiltration in high- B7- H4 module (A). High- B7- H4 module gliomas had 
higher tumor purity (B). Comparison of GSVA score representing the extent of immune cell infiltration between modules 
demonstrated the reduction of immune cells in high- B7- H4 modules (C). GSVA, gene set variation analysis; PD- L1, programmed 
death ligand 1; TCGA, The Cancer Genome Atlas.
We performed IHC staining of CD3 and CD163 in TMA 
cores to determine the presence of TILs and TAMs in 
PD- L1/B7- H4 subgroups, respectively, and found that 
gliomas in the high- B7- H4 subgroup gliomas appeared as 
‘super- cold’ tumors with less TILs and TAMs compared 
with high- PD- L1 subgroup (figure 5 and online supple-
mentary additional file 1: figure S26).
Considering such distinct levels of immune cell infil-
tration among PD- L1/B7- H4 modules, we explored the 
differences between High- PD- L1 module and High- B7- H4 
module gliomas using immune- related gene sets and 
whole genome expression data. The PCA analysis showed 
remarkable differences between High- PD- L1 and High- 
B7- H4 modules in immune phenotype and whole genome 
expression signature for each grade gliomas (online 
supplementary additional file 1: figures S27- S29). Next, 
we detailed these findings with GSEA analysis between 
high- PD- L1 and high- B7- H4 modules. Here, we found 
that many immune response pathways were enriched 
in high- PD- L1 module gliomas, such as T- cell receptor 
signaling pathway, regulation of antigen processing and 
presentation, macrophage differentiation status and toll- 
like receptor signaling pathway (online supplementary 
additional file 1: figure S30). DEGs were obtained within 
each glioma grade from two datasets, and DEGs shared 
between high- PD- L1 and high- B7- H4 modules were iden-
tified (online supplementary additional file 1: figure S31 
and additional file 3: table S15).
dIsCussIon
Previous studies have shown that the majority of gliomas 
expressed PD- L1 with low intensity,8 9 whereas less infor-
mation is known about B7- H4 expression landscape 
in large glioma cohorts. Meanwhile, the coexpression 
status of PD- L1and B7- H4 in gliomas is unknown. In 
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Figure 5 Difference in TILs (CD3 positive cell) density among PD- L1/B7- H4 subgroup gliomas in TMA slides. Representative 
examples of TIL infiltration with CD3+ IHC score: 1, no or sporadic CD3+ cells; 2, moderate numbers of CD3+ cells; 3, abundant 
occurrence of CD3+ cells; and 4, highly abundant occurrence of CD3+ cells (A). Comparation of CD3+ IHC score showed that 
High- B7- H4 subgroup gliomas had less TIL infiltration than high- PD- L1 subgroup gliomas (B). Magnification, ×20 objective; 
Bar, 50 μm. IHC, immunohistochemistry; PD- L1, programmed death ligand 1; TILs, tumor- infiltrating lymphocytes; TMA, tumor- 
associated macrophage.
our current study, protein levels of PD- L1 and B7- H4 
were assessed in 505 glioma patients through IHC anal-
ysis. Although PD- L1 was found to be expressed in the 
majority of this cohort, only 23% had a high expression 
of this protein. Similarly, B7- H4 protein was detected in 
>50% of glioma samples, whereby it was highly expressed 
in 20% of samples. As previously reported in lung and 
breast cancer,13–16 we noticed that coexpression of PD- L1 
and B7- H4 in gliomas was an infrequent event (2%). 
The lack of double- high subgroup (high expression of 
both PD- L1 and B7- H4) suggested that distinct immune 
evasion pathways existed for the glioma subgroups in our 
study. Our findings can be used as a potential strategy for 
targeting these alternative immune checkpoint molecules 
such as B7- H4 in subgroups with low PD- L1 expression.
The limitation of our study is that the IHC glioma 
cohort was selected retrospectively from samples with 
available clinical information. Insufficient tumor repre-
sentation by single core in TMA samples also may have 
induced bias. However, we accounted for this by verifying 
the expression profiles in two different transcriptome 
datasets with correlation analysis and gene coexpression 
modules. Molecular classification based on stable unbi-
ased gene expression clusters has been shown capable 
of identifying intrinsic features around key signaling 
pathways.23 33 Classifier genes demonstrating similar 
gene expression patterns with PD- L1 and B7- H4 were 
identified and shown to be enriched in immune- related 
mechanisms. We believe that the PD- L1/B7- H4 mole-
cules clustered by the classifier genes distinctively acti-
vate the glioma immune microenvironment. In line with 
this, PD- L1/B7- H4 coexpression modules were clustered 
without a double- high module (high expression of both 
PD- L1 and B7- H4 classifier genes), which suggested 
that the mechanisms associated with PD- L1 and B7- H4 
might lead to distinct immunophenotype classification 
of gliomas. We established our coexpression modules in 
each glioma grades, respectively, to reduce the bias from 
WHO grade in this study, which showed the limited coex-
pression pattern and different immune cell infiltrations 
regardless of the WHO grades.
It was previously reported that PD- L1 expression and 
TIL infiltration are distinguishing features for immuno-
therapy sensitivity.34 Classification of TME based on PD- L1 
and TILs determined two major immunophenotypes— 
‘hot and cold tumors’.35 Hot tumors have higher potential 
to benefit from PD-1/PD- L1 blockade or other immuno-
therapies due to existence of tumor- specific T- cells. We 
observed that high- PD- L1 module gliomas exhibited 
more TILs compared with other PD- L1/B7- H4 modules 
in our study. The mesenchymal subtype is considered to 
be more responsive to immune- based therapies because of 
higher number of TILs.36 Accordingly, the mesenchymal 
subtype was mainly clustered in high- PD- L1 modules in 
our study. Therefore, gliomas with high PD- L1 expression 
or PD- L1- related pathways enrichment may potentially 
benefit from PD-1/PD- L1 blockade owing to pre- existing 
TILs. However, previous studies indicated that PD- L1 can 
also be expressed on tumor cells as a result of oncogenic 
signaling, even in the absence of TILs, which can account 
for resistance to PD-1/PD- L1 ICIs immunotherapy regard-
less of high PD- L1 levels.35 In our study, we also observed 
the presence of gliomas harboring significantly less TILs 
within the high- PD- L1 module. A deeper interrogation of 
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these tumors with accurate sub clustering will be instru-
mental for triaging patients using PD-1/PD- L1 inhibitors. 
Furthermore, in our High- PD- L1 module, we found high 
expression of other immunosuppressive molecules, such 
as CTLA-4, TIM3, LAG3 and IDO1, all of which showed 
positive correlation with PD- L1 mRNA levels. Combina-
tion therapies with PD-1/PD- L1 inhibitors and agents 
targeting these immunosuppressive molecules may be 
a promising approach towards eliminating resistance 
against single- agent therapies.2
In contrast to the High- PD- L1 subgroup, high- B7- H4 
gliomas were detected with less TILs and TAMs. Consid-
ering that gliomas have been labeled as ‘cold tumors’ as 
a feature of primary intracranial tumors when compared 
with other solid tumors,37 gliomas with high B7- H4 
expression or B7- H4- related pathways in this study may 
behave as a ‘super- cold’ tumors, which are insensitive to 
existing forms of glioma immunotherapies due to the 
absence of specific TILs. We downloaded RNA- seq data 
from two cohorts of melanoma (n=49)38 and non- small 
cell lung cancer (n=21) patients treated with anti- PD-1 
Abs (online supplementary additional file 4: supplemen-
tary materials and methods), both of which demonstrated 
that higher B7- H4 expression levels in non- responders 
were close to statistical significance (online supplemen-
tary additional file 1: figure S32). Another study also had 
confirmed a negative predictive role of B7- H4 in non- 
small cell lung cancer patients receiving nivolumab based 
on IHC scores.39 Moreover, in our clinical trial for DC 
vaccine in GBM patients, we reported no clinical response 
in patients with high B7- H4 IHC score.4 The data from 
clinical patients mentioned above indicated that treat-
ment with agents targeting B7- H4 or B7- H4- mediated 
immune escape mechanisms may be more effective than 
PD-1/PD- L1 checkpoint inhibitors or DC vaccines alone 
for these tumors. However, the role of B7- H4 in glioma 
immunotherapy or even other brain metastasis tumors 
still deserves further research using larger clinical immu-
notherapy trials and concurrent functional studies, as 
well as the studies exploring development of anti- B7- H4 
immunotherapy protocols. PD- L1/B7- H4 signatures 
demonstrated an underlying association with specific 
relevant immune phenotype classification in gliomas.
ConCLusIons
In summary, we assessed the expression patterns of 
PD- L1 and B7- H4 in a large cohort of glioma patients 
and found mutually exclusive associations between them, 
which is helpful to decipher prominent and nonoverlap-
ping immune escape pathways. Identification of PD- L1/
B7- H4- related gene coexpression modules may be useful 
to define new subtypes of gliomas and elucidating molec-
ular mechanisms underlying tumor immune escape. 
We found B7- H4 expression negatively correlated with 
TILs presence which indicated that B7- H4 might inhibit 
T- cell trafficking into the CNS. Distinct immune micro-
environment profiles between PD- L1/B7- H4 modules 
offers a promising avenue for the development of glioma 
immunotherapy strategies using PD- L1 and B7- H4 as 
biomarkers. Future studies are needed to uncover under-
lying biological mechanisms for alternative immune regu-
latory checkpoints and clinically useful biomarkers such 
as B7- H4, especially in gliomas with low expression of 
PD- L1.
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